Home › Pulmonary Embolism › Texas › San Antonio
Pulmonary Embolism clinical trials in San Antonio, TX
4 studies for Pulmonary Embolism are looking for participants at sites in and around San Antonio (within about 30 miles). Open a study to see who can join and how to contact the study team.
Recruiting for a study here? Feature it at the top of this page — $99 for 30 days →
The PERSEVERE Study
Recruiting
- HCA Methodist Health San Antonio, San Antonio
Study of the Long-Term Safety and Outcomes of Treating Pulmonary Embolism With the Indigo Aspiration System
RecruitingObservational study
- Methodist Hospital Metropolitan, San Antonio
REGN7508 Versus Acetylsalicylic Acid (ASA) for Venous Thromboprophylaxis After Total Knee Arthroplasty in Adult Participants
RecruitingPhase 3
- Flourish Research - San Antonio (Formerly Clinical Trials of Texas), San Antonio
Acute Pulmonary Embolism Treatment With the AlphaVac Multipurpose Mechanical Aspiration System and the AlphaReturn Blood Management System: Evaluation of Safety and Effectiveness
Recruiting
- Methodist Healthcare, San Antonio
About Pulmonary Embolism
A pulmonary embolism is a sudden blockage in a lung artery. The cause is usually a blood clot in the leg called deep vein thrombosis. Learn more.
More about Pulmonary Embolism on MedlinePlus
Pulmonary Embolism trials in other cities
- Boston, MA11 studies
- New York City, NY7 studies
- Cincinnati, OH4 studies
- Philadelphia, PA4 studies
- Knoxville, TN3 studies
- Rochester, MN3 studies
- Houston, TX3 studies
- Miami, FL3 studies
- Dayton, OH3 studies
- Atlanta, GA3 studies
- Indianapolis, IN3 studies
- Norfolk, VA3 studies
Other studies in San Antonio
- Non-Small Cell Lung Cancer60 studies
- Breast Cancer45 studies
- Metastatic Cancer44 studies
- Colorectal Cancer43 studies
- Cancer (all types)41 studies
- Obesity39 studies
- Type 2 Diabetes37 studies
- Overweight34 studies
- Ovarian Cancer33 studies
- Pancreatic Cancer33 studies
- Lung Cancer27 studies
- Prostate Cancer27 studies
From ClinicalTrials.gov, data retrieved Nov 15, 2026. Each study sets its own eligibility; the study team decides who can join.